Safety of bendamustine, etoposide, cytarabine, melphalan (BeEAM) as preconditioning in autologous hematopoietic stem cell transplantation for patients with lymphomas

doi:10.12307/2023.623

Abstract

Abstract: BACKGROUND: In recent years, the application of new drugs such as monoclonal antibodies, small molecule targeted drugs and immunotherapy has significantly improved the short-term efficacy and long-term survival of patients with malignant lymphoma, but autologous hematopoietic stem cell transplantation still plays an important role in the overall treatment of malignant lymphoma. Preconditioning is a very important step in the whole process of autologous hematopoietic stem cell transplantation, but there is no standard preconditioning program at present.
OBJECTIVE: To investigate the safety and effectiveness of Bendamustine, Etoposide, Cytarabine (Melphalan) BeEAM as preconditioning in autologous hematopoietic cell transplantation for patients with lymphomas.
METHODS: From July 5, 2021 to May 31, 2022, 11 patients with lymphoma who underwent autologous hematopoietic stem cell transplantation with BeEAM preconditioning regimen in Department of Hematology of Henan Provincial People’s Hospital were enrolled in the study. The clinical characteristics, pretreating-related non-hematologic toxicity, and hematopoietic reconstitution of the patients were analyzed.
RESULTS AND CONCLUSION: (1) The non-hematological toxicity of BeEAM pretreatment regimen mainly included oral mucositis, diarrhea and fever at granulosa stage, with the incidence of 72.7%, 63.6%, 90.9%, respectively. (2) The median time of neutrophil implantation was 9(8-11) days, and that of platelet implantation was 10(7-16) days. (3) BeEAM pretreatment regimen for autologous hematopoietic stem cell transplantation of lymphoma has controllable non-hematologic toxicity and rapid hematopoietic reconstruction, with transplant-related mortality of 0% at 100 days and transplant-related mortality of 0% at the end of follow-up period, showing good efficacy and safety. Chinese Clinical Trial Registry: identifier No. ChiCTR2100048295.

Key words: Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, autologous hematopoietic stem cell transplantation, preconditioning regimen, non-hematological toxicity, hematopoietic reconstruction

CLC Number:

Kong Dai, Wang Xinkai, Pei Xiaohang, Lian Cheng, Niu Xiaona, Bai Yanliang, Niu Junwei, Zhu Zunmin, Liu Zhongwen. Safety of bendamustine, etoposide, cytarabine, melphalan (BeEAM) as preconditioning in autologous hematopoietic stem cell transplantation for patients with lymphomas[J]. Chinese Journal of Tissue Engineering Research, 2023, 27(19): 2975-2979.

Figures/Tables 2

References

[1] ISIDORI A, CHRISTOFIDES A, VISANI G. Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning. Leuk Lymphoma. 2016;57(11): 2499-2509.
[2] SHI Y, LIU P, ZHOU S, et al. Comparison of CBV, BEAM and BEAC high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation in non-Hodgkin lymphoma: Efficacy and toxicity. Asia Pac J Clin Oncol. 2017;13(5):e423-e429.
[3] QUALLS D, ABRAMSON JS. Advances in risk assessment and prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma. Haematologica. 2019;104(1):25-34.
[4] 中华医学会血液学分会,中国临床肿瘤学会(CSCO)抗淋巴瘤联盟.淋巴瘤自体造血干细胞动员和采集中国专家共识(2020年版)[J].中华血液学杂志,2020,41(12):979-983.
[5] TROTTI A, COLEVAS AD, SETSER A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13(3):176-181.
[6] CHESON BD, PFISTNER B, JUWEID ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-586.
[7] 中国抗癌协会血液肿瘤专业委员会,中华医学会血液学分会白血病淋巴瘤学组,中国临床肿瘤学会抗淋巴瘤联盟.造血干细胞移植治疗淋巴瘤中国专家共识(2018版)[J].中华肿瘤杂志,2018, 40(12):927-934.
[8] MILLS W, CHOPRA R, MCMILLAN A, et al. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin’s lymphoma. J Clin Oncol. 1995;13(3):588-595.
[9] LANE AA, CHEN YB, LOGAN BR, et al. Impact of Conditioning Regimen on Outcomes for Patients with Lymphoma Undergoing High-Dose Therapy with Autologous Hematopoietic Cell Transplantation (AutoHCT). Biol Blood Marrow Transplant. 2014;20(2):S45-S46.
[10] ALESSANDRINO EP, BERNASCONI P, COLOMBO A, et al. Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies. Bone Marrow Transplant. 2000;25(3):309-313.
[11] CAO TM, NEGRIN RS, STOCKERL-GOLDSTEIN KE, et al. Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2000;6(4):387-394.
[12] ISIDORI A, PICCALUGA PP, LOSCOCCO F, et al. High-dose therapy followed by stem cell transplantation in Hodgkin’s lymphoma: past and future. Expert Rev Hematol. 2013;6(4):451-464.
[13] VISANI G, MALERBA L, STEFANI PM, et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood. 2011;118(12):3419-3425.
[14] VISANI G, STEFANI PM, CAPRIA S, et al. Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma. Blood. 2014;124(19):3029-3031.
[15] MITCHELL JL, LIONIKIENE AS, FRASER SR, et al. Functional factor XIII-A is exposed on the stimulated platelet surface. Blood. 2014;124(26):3982-3990.
[16] MARTÍN A, REDONDO AM, VALCÁRCEL D, et al. A Phase 2 Study from Spanish Geltamo Group Investigating the Efficacy and Safety of Bendamustine As Part of Conditioning Regimen for Autologous Stem-Cell Transplantation in Patients with Aggressive Lymphomas: Second Interim Analysis. Blood. 2014;124(21):2524.
[17] VISANI G, GUIDI S, SCALZULLI P, et al. Benda-BEAM High-Dose Therapy Prior to Auto-SCT is Effective in Resistant/Relapsed DLBCL. Biol Blood Marrow Transplant. 2016;22(3):S38.
[18] CHAMBERLAIN MC. Salvage therapy with bendamustine for methotrexate refractory recurrent primary CNS lymphoma: a retrospective case series. J Neurooncol. 2014;118(1):155-162.
[19] RENFROW JJ, DETROYE A, CHAN M, et al. Initial experience with bendamustine in patients with recurrent primary central nervous system lymphoma: a case report. J Neurooncol. 2012;107(3):659-663.
[20] BOEHME V, ZEYNALOVA S, KLOESS M, et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL). Ann Oncol. 2007;18(1):149-157.
[21] SALEH K, DANU A, KOSCIELNY S, et al. A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experience. Leuk Lymphoma. 2018;59(11):2580-2587.
[22] FRANKIEWICZ A, SADUŚ-WOJCIECHOWSKA M, NAJDA J, et al. Comparable safety profile of BeEAM (bendamustine, etoposide, cytarabine, melphalan) and BEAM (carmustine, etoposide, cytarabine, melphalan) as conditioning before autologous haematopoietic cell transplantation. Contemp Oncol (Pozn). 2018;22(2):113-117.
[23] ISIDORI A, LOSCOCCO F, GUIDUCCI B, et al. Benda-EAM prior to ASCT and renal toxicity: Much ado about nothing. Am J Hematol. 2019; 94(4):E104-E105.
[24] CHANTEPIE SP, GARCIAZ S, TCHERNONOG E, et al. Bendamustine-based conditioning prior to autologous stem cell transplantation (ASCT): Results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centers. Am J Hematol. 2018;93(6):729-735.
[25] HUESO T, GASTINNE T, GARCIAZ S, et al. Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers. Bone Marrow Transplant. 2020;55(6):1076-1084.
[26] LACHANCE S, BOURGUIGNON A, BOISJOLY J A, et al. Bendamustine-Based Conditioning Prior to Autologous Hematopoietic Cell Transplant Improves Outcomes in Patients With Elapsed-Refractory Non-Hodgkin Lymphoma[C]//Bone Marrow Transplantation. London: Springernature, 2021;56(SUPPL 1):60-61.